Unity Biotechnology News

All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy

Yahoo Finance00:00

HC Wainwright & Co. : The Unity Biotechnology (UBX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $8.00.

HC Wainwright & Co. : The Unity Biotechnology (UBX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $8.00.

Zhitong FinanceMay 15 23:11

HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $8 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Unity Biotechnology (NASDAQ:UBX) with a Buy and maintains $8 price target.

BenzingaMay 15 23:07

Buy Rating on Unity Biotechnology: Promising Future for UBX1325 in Diabetic Macular Edema Treatment

TipRanksMay 15 18:29

UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates

PDF Version SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or rever

Unity BiotechnologyMay 15 17:00

Unity Biotechnology Q1 EPS $(0.34) Beats $(0.47) Estimate

Unity Biotechnology (NASDAQ:UBX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.47) by 27.66 percent. This is a 55.26 percent increase over losses of $

BenzingaMay 15 05:23

Unity Biotechnology | 10-Q: Quarterly report

SEC announcementMay 15 05:10 · Announcements

Unity Biotechnology Believes Cash, Cash Equivalents and Marketable Securities Sufficient to Fund Ops Into 3Q 2025 >UBX

Unity Biotechnology Believes Cash, Cash Equivalents and Marketable Securities Sufficient to Fund Ops Into 3Q 2025 >UBX

Dow JonesMay 15 05:07

Unity Biotechnology 1Q Loss $5.79M >UBX

Unity Biotechnology 1Q Loss $5.79M >UBX

Dow JonesMay 15 05:00

Press Release: UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates

UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX

Dow JonesMay 15 05:00

UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases

GlobeNewswireApr 25 20:00

UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

PDF Version SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or r

Unity BiotechnologyApr 24 08:00

Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment

Unity Biotechnology (UBX) early Tuesday said phase 2b testing of its UBX1325 drug candidate has been extended by an extra 12 weeks allowing researchers to compare the drug's durability with aflibercep

MT NewswiresApr 23 22:37

UNITY Biotechnology Announces Extension Of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 For Patients In Diabetic Macular Edema

UNITY Biotechnology Announces Extension Of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 For Patients In Diabetic Macular Edema

BenzingaApr 23 20:02

Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwri

BenzingaApr 17 20:21

Unity Biotechnology Is Maintained at Buy by HC Wainwright & Co.

Unity Biotechnology Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 16 19:15

Unity Biotechnology Price Target Cut to $8.00/Share From $10.00 by HC Wainwright & Co.

Unity Biotechnology Price Target Cut to $8.00/Share From $10.00 by HC Wainwright & Co.

Dow JonesApr 16 19:15

HC Wainwright & Co. : The Unity Biotechnology (UBX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $10.00 to $8.00.

HC Wainwright & Co. : The Unity Biotechnology (UBX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $10.00 to $8.00.

Zhitong FinanceApr 16 19:10

HC Wainwright & Co. Maintains Buy on Unity Biotechnology, Lowers Price Target to $8

HC Wainwright & Co. analyst Andrew Fein maintains Unity Biotechnology with a Buy and lowers the price target from $10 to $8.

Analyst UpgradesApr 16 19:05

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)

TipRanksApr 16 18:31